In Vivo Evaluation of Preconditioned Adipose-Derived Stromal Cells Reveals Limited Impact on Vascular and ECM Remodeling in Polymer Scaffolds.
Pinheiro-Machado E., Kuiper T., Huurman RH., Petersen AH., Borghuis T., Smink AM.
Animal Study on Type 1 Diabetes, published in J Biomed Mater Res B Appl Biomater (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Biomed Mater Res B Appl Biomater (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42084008
- DOI
- 10.1002/jbm.b.70088
Abstract (original English)
Polymer scaffolds are a promising platform for the transplantation of insulin-producing cells in Type 1 Diabetes. While vascularization has been a primary focus due to its role in oxygen and nutrient delivery, the interplay between blood vessels and the extracellular matrix (ECM) is increasingly recognized as critical for establishing a stable and functional graft microenvironment. Adipose-derived stromal cells (ASC) have shown potential to support both vascular and ECM remodeling, and their therapeutic profile may be modulated through preconditioning. However, the in vivo effects of ASC preconditioning and their delivery remain poorly defined. This study aims to evaluate whether preconditioned ASC can enhance vascular and ECM outcomes in a polymer scaffold. To this end, rat ASC were preconditioned within porous polycaprolactone (PCL) scaffolds under normoxic, hypoxic, or hypoxic + high-glucose conditions. Subsequently, scaffolds were implanted subcutaneously in immunodeficient rats and explanted at 7, 14, 21, and 28 days for analysis of vascular and ECM markers. This study showed that the addition of ASC did not enhance vascularization or ECM remodeling within the scaffolds, regardless of whether the ASC were preconditioned. This indicates that previously reported in vitro benefits of ASC preconditioning do not necessarily translate in vivo. Moreover, the results highlight the
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care
Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
- 2026
Open Life Sci - Level ASystematic ReviewEurope PMC
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Systematic Review on Type 1 Diabetes, published in Front Transplant (2025) — summary generated from the PubMed abstract.
- 2025
Front Transplant - Level AMeta-analysisEurope PMC
Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
Meta-analysis on Type 1 Diabetes, published in J Diabetes Res (2020) — summary generated from the PubMed abstract.
- 2020
J Diabetes Res7 citations - Level AMeta-analysisEurope PMC
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits
Meta-analysis on Type 1 Diabetes, Type 2 Diabetes, published in Stem Cell Investig (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cell Investig22 citations - Level AMeta-analysisEurope PMC
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
Meta-analysis with a reported sample of 524 on Type 1 Diabetes, published in PLoS One (2016) — summary generated from the PubMed abstract.
- 2016
- n = 524
PLoS One81 citations - Level BClinical TrialEurope PMC
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Clinical Trial on Type 1 Diabetes, Type 2 Diabetes, Scar, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells1 citations